Research programme: fusion proteins - Symphogen
Alternative Names: RB 200; RBLX-200; RBLX-242; Sym 011Latest Information Update: 09 Jun 2020
Price :
$50 *
At a glance
- Originator Receptor BioLogix
- Developer Symphogen
- Class Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action Epidermal growth factor receptor modulators; ERBB-3 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Jun 2020 Symphogen has been acquired by Servier
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Denmark (Parenteral)
- 08 Mar 2011 Preclinical trials in Cancer in Denmark (Parenteral)